KWA
BCLI

Kingswood Wealth Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Kingswood Wealth Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,403
Closed -$45.8K – 662
2024
Q1 		$45.8K Buy
+5,403
New +$29.7K 0.01% 609
2023
Q3 		– Sell
-1,107
Closed -$34.2K – 425
2023
Q2 		$34.2K Buy
+1,107
New +$45.9K 0.01% 265

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Kingswood Wealth Advisors's BCLI Position: Q2 2024 in Review

Kingswood Wealth Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2024, closing a stake of 5,403 shares — an estimated $45.8K sold.

Kingswood Wealth Advisors first reported a position in BCLI in Q2 2023 and held it in 2 quarters. The position peaked at $45.8K in Q1 2024. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2024.

  • Kingswood Wealth Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2024 after selling out during the quarter.
  • Kingswood Wealth Advisors sold 5,403 BRAINSTORM CELL THERAPUTC shares in Q2 2024, an estimated $45.8K.
  • Kingswood Wealth Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2023 and held it in 2 quarters.
  • Kingswood Wealth Advisors's BRAINSTORM CELL THERAPUTC position peaked at $45.8K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2024.

Based on Kingswood Wealth Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.